Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Free Cash Flow (2023 - 2025)

Zenas BioPharma has reported Free Cash Flow over the past 3 years, most recently at -$52.4 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$52.4 million for Q4 2025, down 35.69% from a year ago — trailing twelve months through Dec 2025 was -$172.4 million (down 43.86% YoY), and the annual figure for FY2025 was -$172.4 million, down 43.86%.
  • Free Cash Flow for Q4 2025 was -$52.4 million at Zenas BioPharma, down from -$41.1 million in the prior quarter.
  • Over the last five years, Free Cash Flow for ZBIO hit a ceiling of -$15.4 million in Q4 2023 and a floor of -$52.4 million in Q4 2025.
  • Median Free Cash Flow over the past 3 years was -$37.1 million (2025), compared with a mean of -$34.2 million.
  • Biggest five-year swings in Free Cash Flow: plummeted 150.83% in 2024 and later tumbled 32.41% in 2025.
  • Zenas BioPharma's Free Cash Flow stood at -$15.4 million in 2023, then plummeted by 150.83% to -$38.6 million in 2024, then plummeted by 35.69% to -$52.4 million in 2025.
  • The last three reported values for Free Cash Flow were -$52.4 million (Q4 2025), -$41.1 million (Q3 2025), and -$41.7 million (Q2 2025) per Business Quant data.